Our results suggest USP5 protects MYCN protein from ubiquitin-mediated degradation by lowering unanchored polyubiquitin chain levels in neuroblastoma cells, an effect which can be reversed by direct binding of both drugs to USP5. This evidence concerns the gene MYCN and neuroblastoma.